MedTrace Logo

Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study

NCT06194968 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2024-01-08

No results posted yet for this study

Summary

The purpose of this study is to to compare the safety and effectiveness of IV urokinase with IV alteplase in the treatment of AIS in patients up to 6 hours from symptom onset.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Urokinase

administered intravenously

DRUG

Alteplase

administered intravenously

Sponsors & Collaborators

  • Techpool Bio-Pharma Co., Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-30
Primary Completion
2025-11-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06194968 on ClinicalTrials.gov